797 ROLE OF URINARY NERVE GROWTH FACTOR AS A SPECIFIC BIOMARKER FOR DIAGNOSING AND MONITORING OVERACTIVE BLADDER

Abstract

Listen

Translate article

You have accessJournal of UrologyUrodynamics/Incontinence/Female Urology: Basic Research1 Apr 2011797 ROLE OF URINARY NERVE GROWTH FACTOR AS A SPECIFIC BIOMARKER FOR DIAGNOSING AND MONITORING OVERACTIVE BLADDER Ha Na Lee, Young-Suk Lee, Deok Hyun Han, and Kyu-Sung Lee Ha Na LeeHa Na Lee Seoul, Korea, Republic of More articles by this author , Young-Suk LeeYoung-Suk Lee Changwon, Korea, Republic of More articles by this author , Deok Hyun HanDeok Hyun Han Seoul, Korea, Republic of More articles by this author , and Kyu-Sung LeeKyu-Sung Lee Seoul, Korea, Republic of More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.615AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Urinary nerve growth factor (NGF) levels are known to be increased in overactive bladder (OAB) and decreased with the antimuscarinic treatment. We investigated the urinary NGF levels in OAB patients and monitored the urinary NGF levels before and after the antimuscarinic medication. METHODS Urinary NGF level were evaluated in OAB patients and control group (without OAB symptoms). In OAB group, participants were rechecked their urinary NGF levels after the 12-week treatment with anticholinergics or placebo. All NGF level were corrected by urinary creatinine (Cr) levels which were measured at the same time. Patients treated were grouped according to the change of 3-day micturition diaries; improvement group-the patient who decreased their voiding frequency ≥2/24 hours and urgency >50%. The level of NGF/Cr was compared between improvement group and non-improvement group. Urinary NGF levels were measured by enzyme-linked immunosorbent assay (ELISA). RESULTS Urine samples from 94 participants were collected: 34 control, 60 OAB patients (anticholinergic: 46, placebo: 14). Mean urinary NGF/Cr level in OAB group was 0.47¡Ó0.50, which was significantly elevated compared with the control group (0.21±0.23, p=0.000). In placebo group, there was no significant change in urinary NGF/Cr level after treatment (p=0.470) (Table). Also in anticholonergic group, urinary NGF/Cr level was not significantly changed after treatment (p=0.149). Patient¡¦s symptoms were significantly improved with anticholinergic medication. Mean frequency, urgency episodes, urgency severity were improved from 10.9±2.1, 6.8±3.4, 2.8±0.6 at baseline to 8.4±1.8, 4.3±3.8, 2.4±0.7 after the treatment (p<0.05). Symptom improvement and the change of mean NGF/Cr was not correlated (improvement group 17, non-improvement group 25). In placebo group, there was no significant change in micturition diaries. The change of urine NGF/Cr level according to the treatment of anticholinergics or placebo N baseline 12 weeks later p-value OAB group 60 0.465⁎>0.497 Anticholinergics treatment 46 0.505>0.556 0.647>0.695 0.149 solifecacin 19 0.251>0.187 0.517>0.675 0.095 tolterodine 27 0.683>0.656 0.739>0.708 0.509 Placebo 14 0.334>0.214 0.314>0.194 0.470 Control group 34 0.21>0.231 ⁎ p < 0.05, compared to control group. CONCLUSIONS Urinary NGF/Cr levels were elevated in OAB patients, but there was no absolute correlation of NGF level with anticholinergics medication. NGF may be the specific biomarker for diagnosing OAB. However, urinary NGF may not be a sensitive marker to monitor the efficacy of the anticholinergics in OAB. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e321 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ha Na Lee Seoul, Korea, Republic of More articles by this author Young-Suk Lee Changwon, Korea, Republic of More articles by this author Deok Hyun Han Seoul, Korea, Republic of More articles by this author Kyu-Sung Lee Seoul, Korea, Republic of More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...